Table 3.
rtg2Δ does not inhibit [URE3] propagation or curing
| Cytoduction 1
|
Guanidine treatment | Cytoduction 2 USA+/total | |
|---|---|---|---|
| Donor | Recipient | ||
| None | MP29 RTG2 [URE3] | − | 13/13 |
| None | MP27 rtg2Δ | − | 0/9 |
| None | MP28 (rtg2Δ) | − | 0/12 |
| [URE3] → | MP71 RTG2 [ure-o] | − | 6/6 |
| [URE3] → | MP71 RTG2 [ure-o] | + | 0/17 |
| [URE3] → | MP27 rtg2Δ | − | 8/8 |
| [URE3] → | MP27 rtg2Δ | + | 0/12 |
| [URE3] → | MP28 rtg2Δ | − | 10/10 |
| [URE3] → | MP28 rtg2Δ | + | 0/5 |
Propagation of [URE3] was tested by using a two-stage cytoduction experiment of the type: [URE3] → RTG+ or rtg2Δ → [ure-o]. In the first cytoduction, cytoplasm was transferred from the [URE3] donor strains 4184 or 4833-3B to ρo RTG2 and rtg2Δ strains. Haploid recipients that acquired a functional mitochondrial genome were grown either in the presence or absence of 5 mM guanidine and then used as donors in a second cytoduction to guanidine-cured ρo derivatives of 4184 or 4833-3B. The number of USA+ cytoductants/total cytoductants observed in the second cytoduction is shown. The presence of USA+ cytoductants from the second cytoduction confirms the ability of donor strains to propagate [URE3].